Dr. Yardley on BOLERO-2 Results for HR+ Breast Cancer

Denise A. Yardley, MD
Published: Tuesday, Nov 28, 2017



Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the BOLERO-2 results for patients with hormone receptor (HR)-positive breast cancer.

According to Yardley, hormone resistance is an important area for patients with HR-positive breast cancer. Data from the BOLERO-2 study made the combination of everolimus (Afinitor) and exemestane a standard of care for patients who were failing endocrine therapy.

Additionally, CDK4/6 inhibitors have rolled out in advanced patients in the second-line setting, explains Yardley.
 


Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the BOLERO-2 results for patients with hormone receptor (HR)-positive breast cancer.

According to Yardley, hormone resistance is an important area for patients with HR-positive breast cancer. Data from the BOLERO-2 study made the combination of everolimus (Afinitor) and exemestane a standard of care for patients who were failing endocrine therapy.

Additionally, CDK4/6 inhibitors have rolled out in advanced patients in the second-line setting, explains Yardley.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x